Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Biden during a meeting with other leaders from the "Quad." Photo: Alex Wong/Getty Images

The U.S. will begin sharing its full inventory of AstraZeneca vaccine doses with countries around the world once an FDA safety review is complete, AP reports.

Why it matters: The Biden administration had been under intense global pressure for refusing to share its stockpile of the AstraZeneca vaccine, which is critical to vaccine rollouts in countries like India but not approved for use in the U.S. Per AP, the administration now expects to be able to share around 60 million doses in the coming months.

What they're saying:

  • White House COVID-19 coordinator Jeff Zients told AP: “Given the strong portfolio of vaccines that the U.S. already has and that have been authorized by the FDA, and given that the AstraZeneca vaccine is not authorized for use in the U.S., we do not need to use the AstraZeneca vaccine here during the next several months. Therefore the U.S. is looking at options to share the AstraZeneca doses with other countries as they become available.”
  • White House COVID-19 adviser Andy Slavitt tweeted: "To everyone who understandably says: 'about time' or 'what were they waiting for', at this time there are still very few available. No real time has been lost."

The state of play: The U.S. has thus far shared just four million AstraZeneca vaccines, sending doses to Mexico and Canada.

  • Both U.S. neighbors have requested additional supplies, as have a number of other countries. Zients said the White House has not yet determined where the doses will go.
  • He also said the FDA review of the vaccine should conclude within the next several weeks.

The big picture: The U.S. is one of the world's four major producers of coronavirus vaccines — along with China, India and the EU — and the only one that has not exported a significant number of doses.

  • In addition to keeping nearly all doses produced in the U.S. at home, President Biden also used the Defense Production Act to ensure priority access to the raw materials needed to produce vaccines.
  • That has led to allegations of "vaccine nationalism" from countries around the world, many of which have yet to begin their vaccine rollouts in earnest.
  • Those charges have gained increased intensity during the brutal second wave in India, with the Biden administration belatedly offering on Sunday to ship supplies to help the country cope.

What to watch: Demand for vaccines is beginning to fall sharply in the U.S., but the Pfizer, Moderna and J&J vaccines remain in short supply elsewhere around the world.

  • On the one hand: Secretary of State Tony Blinken has said the U.S. will become "the world leader in helping to make sure that the entire world gets vaccinated."
  • On the other: The White House has said it will prioritize the needs of Americans and build slack into the system for potential booster shots, to potentially vaccinate children, and to address other domestic needs as they arise.

The bottom line: Global requests for U.S.-made vaccines will only grow louder even after Biden starts shipping AstraZeneca doses.

Go deeper

Apr 26, 2021 - World

European Commission sues AstraZeneca for vaccine shortages

Photo: Thierry Monasse/Getty Images

The European Commission has launched legal proceedings against AstraZeneca for providing only a third of the supply of coronavirus vaccines agreed to in its contract, a spokesperson confirmed Monday.

Why it matters: It's the latest in a string of controversies related to the European Union's vaccine rollout, which has been plagued by supply shortages, a slow pace of distribution, and concerns about potential rare blood clots linked to AstraZeneca and Johnson & Johnson.

Apr 26, 2021 - Health

Sanofi to manufacture 200 million Moderna COVID vaccines in U.S.

Photo: Ty O'Neil/SOPA Images/LightRocket via Getty Images

Sanofi announced Monday it will manufacture up to 200 million doses of Moderna's COVID-19 vaccine at its site in Ridgefield, New Jersey, from September.

Why it matters: The agreement between Sanofi and Moderna should not only boost the U.S. coronavirus vaccine rollout, it should also help global efforts as the doses will likely be exported.